Skip to main content

Table 1 Baseline cohort characteristics

From: The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal

Characteristic

PIONEER 2 (oral semaglutide versus empagliflozin)

PIONEER 3 (oral semaglutide versus dulaglutide)

Start age (years)

57.63 (9.94)

57.86 (9.87)

Duration of diabetes (years)

7.00 (6.09)*

9.00 (5.98)*

Percentage male (%)

50.55

52.82

HbA1c (%)

8.14 (0.94)

8.31 (0.92)

Systolic blood pressure (mmHg)

132.15 (14.69)

133.83 (15.41)

BMI (kg/m2)

32.82 (6.11)

32.49 (6.41)

Percentage smokers (%)

14.62

14.17

Cigarettes per day

13.00*,†

Alcohol consumption (oz/week)

7.97†

  1. BMI: body mass index; HbA1c: glycated hemoglobin
  2. *Rounded values, as the IQVIA CORE Diabetes Model only accepts integers for these parameters
  3. †Based on Portugal-specific data as not available from the PIONEER trial program
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us